Queensland TACSGP

Queensland Translation and Commercialisation Skills Gap Program (TACSGP)

The Queensland Translation and Commercialisation Skills Gap Program is for Queensland-based biomed founders or early-stage businesses.

The program is a strategic collaboration between Brandon Capital and the Queensland Government’s Department of State Development and Infrastructure under their Biomedical Roadmap initiative.

Program Purpose

Brandon BioCatalyst will guide a limited cohort of companies and entrepreneurs on a transformative journey that culminates in the opportunity to attend BIO2024 in San Diego (at your own expense).  Brandon BioCatalyst will work with TIQ to provide the Cohort with an opportunity to present at the Queensland Investor Roundtable event at BIO 2024.

The seminar portion of the program is open to all.

What to expect?

📚 A four-part seminar series covering pivotal subjects like pre-commercialization planning, early preclinical development, clinical and regulatory strategy, and company formation, investment, and partnering.

🔧 Beyond Seminars: Practical workshops exploring business planning, CUREator grants, clinical and regulatory development, and BIO preparation and planning.

🤝 You’ll have access to the globally connected Brandon BioCatalyst team, who will help you navigate the early stages of innovation, driving towards commercialization outcomes, including investment and partnerships.

Seminar Series

The seminar series portion of the program is open to all.

Tuesday 27 February 2024 – Preparing yourself for clinical translation: An introduction to a Target Product Profile (TPP) & The importance of picking the right target: Perspectives from Pharma and Start up.

Therapeutic development planning, early commercialisation considerations and spin out creation. After lunch the Cohort will have a session on business planning and Target Product Profiles from a Pharmaceutical perspective presented by ex GSK VP and Head of Biology and current Brandon Capital Venture Partner Dr Roberto Solari and Analyst Dr Melissa Byrne.

Thursday 21 March 2024- Research discoveries into drug development programs.

Cover the formal pre-clinical development requirements to support translation.  Join Dr Ian Holmes and Dr Melissa Byrne in a session, where they will share their expertise on small molecule drug discovery and considerations in preclinical development.

Ian will present an overview with personal experiences and anecdotes in small molecule drug discovery, including formal and informal phases and stages based on his pharmaceutical experience.

Tuesday 23 April 2024 – Translating research to the Clinic

Join Brandon Capital Senior Investment Manager Bob Soh M.D. and Brandon Capital Analyst Dr Melissa Byrne in a session that will for preparing for and completing clinical development activities, including regulatory aspects and designing and conducting clinical trials.

Tuesday 7 May 2024 – Company build and investment: Legal, cultural and practical considerations

The session, which encludes a leadership characteristics and training session will be delivered by Drs Chris Smith and Goslik Schepers from Brandon Capital.  In it, they cover early-stage to mid-stage capital raising, type of funding, Venture Capital funding trends, styles, considerations, partnering strategy types and execution.

RSVP to attend here.

Seminar timing and location

All sessions run from 10 am to 12 pm at the  Translational Research Institute Auditorium, Translational Research Institute, 37 Kent Street, Woolloongabba, QLD, 4106 with a light lunch to follow.

When do applications close?

Applications for the 2024 cohort are now closed.  You are welcome to join the seminar series in preparation for the 2025 intake.